BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities.
"Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient and appropriate under the statute," said BIO's EVP for Health and Policy Programs, Phyllis Arthur. "A 340B rebate is, and should be, among the legally permissible options. We strongly support efforts that could bring the type of transparency needed to protect the integrity of the program.”
A copy of BIO's prior letter to HRSA is available here: https://www.bio.org/letters-testimony-comments/bio-letter-hrsa-340b-rebate-model
About BIO
BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org